vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($177.4M vs $168.4M, roughly 1.1× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 5.0%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs -0.2%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
ESPR vs PCRX — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $177.4M |
| Net Profit | — | $2.9M |
| Gross Margin | — | — |
| Operating Margin | 50.6% | 3.9% |
| Net Margin | — | 1.6% |
| Revenue YoY | 143.7% | 5.0% |
| Net Profit YoY | — | — |
| EPS (diluted) | $0.32 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $168.4M | $196.9M | ||
| Q3 25 | $87.3M | $179.5M | ||
| Q2 25 | $82.4M | $181.1M | ||
| Q1 25 | $65.0M | $168.9M | ||
| Q4 24 | $69.1M | $187.3M | ||
| Q3 24 | $51.6M | $168.6M | ||
| Q2 24 | $73.8M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | — | — | ||
| Q3 25 | $-31.3M | $5.4M | ||
| Q2 25 | $-12.7M | $-4.8M | ||
| Q1 25 | $-40.5M | $4.8M | ||
| Q4 24 | — | — | ||
| Q3 24 | $-29.5M | $-143.5M | ||
| Q2 24 | $-61.9M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | — | 79.5% | ||
| Q3 25 | — | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | — | 79.7% | ||
| Q4 24 | — | 78.7% | ||
| Q3 24 | — | 76.9% | ||
| Q2 24 | — | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | 50.6% | 1.2% | ||
| Q3 25 | -11.4% | 3.5% | ||
| Q2 25 | 8.6% | 4.7% | ||
| Q1 25 | -34.0% | 1.2% | ||
| Q4 24 | -6.4% | 13.2% | ||
| Q3 24 | -31.0% | -82.8% | ||
| Q2 24 | 3.5% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | — | — | ||
| Q3 25 | -35.9% | 3.0% | ||
| Q2 25 | -15.4% | -2.7% | ||
| Q1 25 | -62.2% | 2.8% | ||
| Q4 24 | — | — | ||
| Q3 24 | -57.2% | -85.1% | ||
| Q2 24 | -83.9% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $0.32 | $0.05 | ||
| Q3 25 | $-0.16 | $0.12 | ||
| Q2 25 | $-0.06 | $-0.11 | ||
| Q1 25 | $-0.21 | $0.10 | ||
| Q4 24 | $-0.14 | $0.38 | ||
| Q3 24 | $-0.15 | $-3.11 | ||
| Q2 24 | $-0.33 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | $653.9M |
| Total Assets | $465.9M | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $167.9M | $238.4M | ||
| Q3 25 | $92.4M | $246.3M | ||
| Q2 25 | $86.1M | $445.9M | ||
| Q1 25 | $114.6M | $493.6M | ||
| Q4 24 | $144.8M | $484.6M | ||
| Q3 24 | $144.7M | $453.8M | ||
| Q2 24 | $189.3M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $-302.0M | $693.1M | ||
| Q3 25 | $-451.4M | $727.2M | ||
| Q2 25 | $-433.5M | $757.8M | ||
| Q1 25 | $-426.2M | $798.5M | ||
| Q4 24 | $-388.7M | $778.3M | ||
| Q3 24 | $-370.2M | $749.6M | ||
| Q2 24 | $-344.2M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $465.9M | $1.3B | ||
| Q3 25 | $364.0M | $1.3B | ||
| Q2 25 | $347.1M | $1.5B | ||
| Q1 25 | $324.0M | $1.6B | ||
| Q4 24 | $343.8M | $1.6B | ||
| Q3 24 | $314.1M | $1.5B | ||
| Q2 24 | $352.3M | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | 0.0% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $45.2M | $43.7M | ||
| Q3 25 | $-4.3M | $60.8M | ||
| Q2 25 | $-31.4M | $12.0M | ||
| Q1 25 | $-22.6M | $35.5M | ||
| Q4 24 | $-35.0M | $33.1M | ||
| Q3 24 | $-35.3M | $53.9M | ||
| Q2 24 | $-7.2M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $43.5M | ||
| Q3 25 | — | $57.0M | ||
| Q2 25 | — | $9.3M | ||
| Q1 25 | — | $26.9M | ||
| Q4 24 | — | $31.0M | ||
| Q3 24 | $-35.5M | $49.8M | ||
| Q2 24 | $-7.3M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | — | 22.1% | ||
| Q3 25 | — | 31.7% | ||
| Q2 25 | — | 5.1% | ||
| Q1 25 | — | 15.9% | ||
| Q4 24 | — | 16.6% | ||
| Q3 24 | -68.7% | 29.6% | ||
| Q2 24 | -9.9% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 0.0% | 0.1% | ||
| Q3 25 | 0.0% | 2.2% | ||
| Q2 25 | 0.0% | 1.5% | ||
| Q1 25 | 0.0% | 5.1% | ||
| Q4 24 | 0.0% | 1.1% | ||
| Q3 24 | 0.3% | 2.4% | ||
| Q2 24 | 0.1% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 11.20× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 7.37× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
